1. Emerging Advances in Reducing Renal Complications of T2D

3. Gaps in Current Management of CKD and T2D

4. SGLT2 Inhibitors for T2D

5. Many Renal Effects of SGLT2 Inhibition Have Been Proposed

6. CVOTs for SGLT2 Inhibitors Published So Far

7. CVOT: EMPA-REG OUTCOME and Subanalyses Empagliflozin

8. CVOT: CANVAS Program and Subanalyses Canagliflozin

9. CANTANA-SU Trial Canagliflozin Renal Subanalyses

10. CVOT: DECLARE-TIMI 58 and Subanalyses Dapagliflozin

11. Timeline of Major SGLT2 Inhibitor Trials

12. Higher Renal Risk Population in CREDENCE

13. CREDENCE: First Dedicated Renal Outcomes Trial in T2D Published

14. CREDENCE: Study Design

15. CREDENCE: Primary and Secondary Endpoints

16. CREDENCE: Interim Analysis

17. CREDENCE: Key Patient Demographics and Disease History

18. CREDENCE: Effect on Intermediate Outcomes

19. Rate of Decline in Kidney Function by BP From Clinical Trials

20. CREDENCE: Summary of the Impact on Renal Events

21. CREDENCE: eGFR Slope

22. CREDENCE: Summary Of the Impact on CV Events

23. CREDENCE: Safety

24. CREDENCE: Other AEs of Interest

25. Patient Education on Key AEs of the SGLT2 Inhibitor Class

26. Impact of CREDENCE and CVOT Data on Clinical Practice

27. The Future of DKD Treatment

28. Abbreviations

29. Abbreviations (cont)